NXL Nexalin Technology, Inc.
Healthcare$0.48+27.11%ClosedMarket Cap: $9.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.59
P/S
28.21
EV/EBITDA
-0.78
DCF Value
$-0.29
FCF Yield
-68.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-102.9%
Operating Margin
-3084.2%
Net Margin
-3022.9%
ROE
-191.9%
ROA
-225.5%
ROIC
-294.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $14.9K | -3319.5% | $-2.1M | $-2.1M | $— | — |
| Q4 null | $171.9K | 87.8% | $-2.4M | $-2.4M | $— | — |
| FY null | $301.6K | 79.7% | $-8.4M | $-8.2M | $— | — |
| Q3 null | $18.1K | 78.2% | $-2.3M | $-2.3M | $— | — |
| Q2 null | $70.6K | 67.6% | $-1.6M | $-1.6M | $— | — |
| Q1 null | $41.0K | 66.9% | $-2.0M | $-2.0M | $— | — |
| Q4 null | $27.2K | 72.4% | $-2.9M | $-2.8M | $— | — |
| FY null | $168.7K | 78.3% | $-7.8M | $-7.6M | $— | — |
| Q3 null | $36.0K | 64.8% | $-2.5M | $-2.4M | $— | — |
| Q2 null | $26.8K | 73.0% | $-1.3M | $-1.3M | $— | — |
| Q1 null | $78.7K | 88.4% | $-1.1M | $-1.0M | $— | — |
| Q4 2023 | $20.5K | 74.5% | $-1.6M | $-780.7K | $-0.10 | — |